清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

医学 奥拉帕尼 同源重组 内科学 药品 PARP抑制剂 肿瘤科 生活质量(医疗保健) DNA修复 前列腺癌 激素疗法 癌症研究 基因 激素 前列腺 癌症 化疗 转移 聚ADP核糖聚合酶
作者
Antoine Thiery-Vuillemin,Johann Sebastian De Bono,Maha Hussain,Guilhem Roubaud,Giuseppe Procopio,Neal Shore,Karim S. Fizazi,Gabriel Marques dos Anjos,Gwénaëlle Gravis,Jae Young Joung,Nobuaki Matsubara,Daniel Castellano,Arnold Degboe,Chris Gresty,Jinyu Kang,Allison Allen,Christian Poehlein,Fred Saad C
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (3): 393-405 被引量:41
标识
DOI:10.1016/s1470-2045(22)00017-1
摘要

The PROfound study showed significantly improved radiographical progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer with alterations in homologous recombination repair genes and disease progression on a previous next-generation hormonal drug who received olaparib then those who received control. We aimed to assess pain and patient-centric health-related quality of life (HRQOL) measures in patients in the trial.In this open-label, randomised, phase 3 study, patients (aged ≥18 years) with metastatic castration-resistant prostate cancer and gene alterations to one of 15 genes (BRCA1, BRCA2, or ATM [cohort A] and BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, and RAD54L [cohort B]) and disease progression after a previous next-generation hormonal drug were randomly assigned (2:1) to receive olaparib tablets (300 mg orally twice daily) or a control drug (enzalutamide tablets [160 mg orally once daily] or abiraterone tablets [1000 mg orally once daily] plus prednisone tablets [5 mg orally twice daily]), stratified by previous taxane use and measurable disease. The primary endpoint (radiographical progression-free survival in cohort A) has been previously reported. The prespecified secondary endpoints reported here are on pain, HRQOL, symptomatic skeletal-related events, and time to first opiate use for cancer-related pain in cohort A. Pain was assessed with the Brief Pain Inventory-Short Form, and HRQOL was assessed with the Functional Assessment of Cancer Therapy-Prostate (FACT-P). All endpoints were analysed in patients in cohort A by modified intention-to-treat. The study is registered with ClinicalTrials.gov, NCT02987543.Between Feb 6, 2017, and June 4, 2019, 245 patients were enrolled in cohort A and received study treatment (162 [66%] in the olaparib group and 83 [34%] in the control group). Median duration of follow-up at data cutoff in all patients was 6·2 months (IQR 2·2-10·4) for the olaparib group and 3·5 months (1·7-4·9) for the control group. In cohort A, median time to pain progression was significantly longer with olaparib than with control (median not reached [95% CI not reached-not reached] with olaparib vs 9·92 months [5·39-not reached] with control; HR 0·44 [95% CI 0·22-0·91]; p=0·019). Pain interference scores were also better in the olaparib group (difference in overall adjusted mean change from baseline score -0·85 [95% CI -1·31 to -0·39]; pnominal=0·0004). Median time to progression of pain severity was not reached in either group (95% CI not reached-not reached for both groups; HR 0·56 [95% CI 0·25-1·34]; pnominal=0·17). In patients who had not used opiates at baseline (113 in the olaparib group, 58 in the control group), median time to first opiate use for cancer-related pain was 18·0 months (95% CI 12·8-not reached) in the olaparib group versus 7·5 months (3·2-not reached) in the control group (HR 0·61; 95% CI 0·38-0·99; pnominal=0·044). The proportion of patients with clinically meaningful improvement in FACT-P total score during treatment was higher for the olaparib group than the control group: 15 (10%) of 152 evaluable patients had a response in the olaparib group compared with one (1%) of evaluable 77 patients in the control group (odds ratio 8·32 [95% CI 1·64-151·84]; pnominal=0·0065). Median time to first symptomatic skeletal-related event was not reached for either treatment group (olaparib group 95% CI not reached-not reached; control group 7·8-not reached; HR 0·37 [95% CI 0·20-0·70]; pnominal=0·0013).Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound.AstraZeneca and Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美好的飞兰完成签到,获得积分10
1秒前
爆米花的应助被369ninja采纳,获得10
2秒前
16秒前
JUN完成签到,获得积分10
23秒前
瞿人雄完成签到,获得积分10
28秒前
没心没肺完成签到,获得积分10
32秒前
Jasper的应助被科研通管家采纳,获得10
34秒前
34秒前
丘比特的应助被科研通管家采纳,获得10
34秒前
上官若男的应助被科研通管家采纳,获得10
34秒前
Ava的应助被科研通管家采纳,获得10
34秒前
大意的之柔完成签到,获得积分10
37秒前
39秒前
42秒前
369ninja发布了新的文献求助10
47秒前
可靠往事完成签到,获得积分10
49秒前
自由的梦山完成签到,获得积分10
59秒前
喜悦如萱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
学霸业的应助被369ninja采纳,获得10
1分钟前
369ninja发布了新的文献求助10
1分钟前
1分钟前
43tg完成签到,获得积分10
1分钟前
qfhbg完成签到,获得积分10
2分钟前
落后哈密瓜完成签到,获得积分10
2分钟前
wetg完成签到,获得积分10
2分钟前
学霸业的应助被369ninja采纳,获得10
2分钟前
portik完成签到,获得积分10
2分钟前
要减肥的菀完成签到,获得积分10
2分钟前
hgjk完成签到,获得积分10
2分钟前
2分钟前
sdf完成签到,获得积分10
2分钟前
VDC的应助被369ninja采纳,获得30
2分钟前
amz完成签到,获得积分10
2分钟前
adefgv完成签到,获得积分10
2分钟前
科目三的应助被科研通管家采纳,获得10
2分钟前
fhjg完成签到,获得积分10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179961
求助须知:如何正确求助?哪些是违规求助? 9570183
关于积分的说明 21808480
捐赠科研通 7775832
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557373
邀请新用户注册赠送积分活动 2478958